3.37
-0.055(-1.61%)
Currency In USD
| Previous Close | 3.42 |
| Open | 3.43 |
| Day High | 3.43 |
| Day Low | 3.33 |
| 52-Week High | 3.8 |
| 52-Week Low | 1.38 |
| Volume | 14,346 |
| Average Volume | 1.03M |
| Market Cap | 282.47M |
| PE | -3.58 |
| EPS | -0.94 |
| Moving Average 50 Days | 3.19 |
| Moving Average 200 Days | 2.15 |
| Change | -0.06 |
aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2024 1:00 PM GMT
SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announce
aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors
GlobeNewswire Inc.
Dec 12, 2024 9:00 PM GMT
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetas
aTyr Pharma Announces Third Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
GlobeNewswire Inc.
Dec 10, 2024 1:00 PM GMT
Independent data and safety monitoring board (DSMB) review includes all 268 patients who have been enrolled in the study and recommends continuation of study without any modifications.SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (